ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents SUBCOMMITTEE ON ATTENTION-DEFICIT/HYPERACTIVITY DISORDER, STEERING COMMITTEE ON QUALITY IMPROVEMENT AND MANAGEMENT

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood and can profoundly affect the academic achievement, well-being, and social interactions of children; the American Academy of Pediatrics first published clinical recommendations for the diagnosis and evaluation of ADHD in children in 2000; recommendations for treatment followed in 2001. SUBCOMMITTEE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (OVERSIGHT BY THE STEERING COMMITTEE ON QUALITY IMPROVEMENT AND MANAGEMENT, 2005–2011) WRITING COMMITTEE Mark Wolraich, MD, Chair – (periodic consultant to Shire, Eli Lilly, Shinogi, and Next Wave Pharmaceuticals) Lawrence Brown, MD – (neurologist; AAP Section on Neurology; Child Neurology Society) (Safety Monitoring Board for Best Pharmaceuticals for Children Act for National Institutes of Health) Ronald T. Brown, PhD – (child psychologist; Society for Pediatric Psychology) (no conflicts) George DuPaul, PhD – (school psychologist; National Association of School Psychologists) (participated in clinical trial on Vyvanse effects on college students with ADHD, funded by Shire; published 2 books on ADHD and receives royalties) Marian Earls, MD – (general pediatrician with QI expertise, developmental and behavioral pediatrician) (no conflicts) Heidi M. Feldman, MD, PhD – (developmental and behavioral pediatrician; Society for Developmental and Behavioral Pediatricians) (no conflicts) Theodore G. Ganiats, MD – (family physician; American Academy of Family Physicians) (no conflicts) Beth Kaplanek, RN, BSN – (parent advocate, Children and Adults With Attention Deficit Hyperactivity Disorder [CHADD]) (no conflicts) Bruce Meyer, MD – (general pediatrician) (no conflicts) James Perrin, MD – (general pediatrician; AAP Mental Health Task Force, AAP Council on Children With Disabilities) (consultant to Pfizer not related to ADHD) Karen Pierce, MD – (child psychiatrist; American Academy of Child and Adolescent Psychiatry) (no conflicts) Michael Reiff, MD – (developmental and behavioral pediatrician; AAP Section on Developmental and Behavioral Pediatrics) (no conflicts) Martin T. Stein, MD – (developmental and behavioral pediatrician; AAP Section on Developmental and Behavioral Pediatrics) (no conflicts) Susanna Visser, MS – (epidemiologist) (no conflicts) CONSULTANT Melissa Capers, MA, MFA – (medical writer) (no conflicts) STAFF Caryn Davidson, MA This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication. The recommendations in this report do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate. All clinical practice guidelines from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time. HHS Public Access Author manuscript Pediatrics. Author manuscript; available in PMC 2015 July 13. Published in final edited form as: Pediatrics. 2011 November ; 128(5): 1007–1022. doi:10.1542/peds.2011-2654. A uhor M anscript